Replication-deficient adenovirus induces aost topoisomerase I activity: Implications for adenovirus-mediated gene expression

Molecular Therapy

Volumn 15, Issue 4, 2007, Pages 772-781

  Zamir, Gideon ^a   Zeira, Evelyne ^a   Gelman, Andrew E ^b   Shaked, Abraham ^b   Olthoff, Kim M ^b   Eid, Ahmed ^a   Galun, Eithan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; DNA TOPOISOMERASE; ETOPOSIDE; HYDROXYUREA; NUCLEAR PROTEIN; PLACEBO; PLASMID DNA; TOPOTECAN; VIRUS DNA;

ANIMAL CELL; ARTICLE; BAGG ALBINO MOUSE; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN HEPG2; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO GENE TRANSFER; FEMALE; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEWIS RAT; LIVER; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; RAT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CELL LINE; DEFECTIVE VIRUSES; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER; MICE; MICE, INBRED BALB C; NEOPLASMS; RATS; RATS, INBRED LEW; TOPOTECAN; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; RATTUS;

EID: 33947194274     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300110     Document Type: Article

References (41)

1. Jaffe, HA, Danel, C, Longenecker, G, Metzger, M, Setoguchi, Y, Rosenfeld, MA et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1: 372-378.
2. Zhang, Y, Chirmule, N, Gao, GP, Qian, R, Croyle, M, Joshi, B et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3: 697-707.
3. Sung, RS, Qin, L and Bromberg, JS (2001). TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther 3: 757-767.
4. Worgall, S, Wolff, G, Falck-Pedersen, E and Crystal, RG (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37-44.
5. Yang, Y, Nunes, FA, Berencsi, K, Furth, EE, Gonczol, E and Wilson, JM (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411.
6. Gao, GP, Yang, Y and Wilson, JM (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70: 8934-8943.
7. Bett, AJ, Haddara, W, Prevec, L and Graham, FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802-8806.
8. Toth, K, Doronin, K, Tollefson, AE and Wold, WS (2003). A multitasking oncolytic adenovirus vector. Mol Ther 7: 435-437.
9. Green, NK and Seymour, LW (2002). Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Ther 9: 1036-1042.
10. Reid, T, Warren, R and Kirn, D (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 9: 979-986.
11. Gupta, M, Fujimori, A and Pommier, Y (1995). Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1262: 1-14.
12. Leppard, JB and Champoux, JJ (2005). Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 114: 75-85.
13. Soret, J, Gabut, M, Dupon, C, Kohlhagen, G, Stevenin, J, Pommier, Y et al. (2003). Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res 63: 8203-8211.
14. Pilch, B, Allemand, E, Facompre, M, Bailly, C, Riou, JF, Soret, J et al. (2001). Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 61: 6876-6884.
15. Wang, JC (2002). Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 3: 430-440.
16. Wang, JC (1996). DNA topoisomerases. Annu Rev Biochem 65: 635-692.
17. Seidman, MA, Hogan, SM, Wendland, RL, Worgall, S, Crystal, RG and Leopold, PL (2001). Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 4: 13-21.
18. Bernt, KM, Steinwaerder, DS, Ni, S, Li, ZY, Roffler, SR and Lieber, A (2002). Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 62: 6089-6098.
19. Chow, KC and Pearson, GD (1985). Adenovirus infection elevates levels of cellular topoisomerase I. Proc Natl Acad Sci USA 82: 2247-2251.
20. Romig, H and Richter, A (1990). Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells. Nucleic Acids Res 18: 801-808.
21. Schaack, J, Schedl, P and Shenk, T (1990). Topoisomerase I and II cleavage of adenovirus DNA in vivo: Both topoisomerase activities appear to be required for adenovirus DNA replication. J Virol 64: 78-85.
22. Schaak, J, Schedl, P and Shenk, T (1990). Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function. Nucleic Acids Res 18: 1499-1508.
23. Emerson, DL, Besterman, JM, Brown, HR, Evans, MG, Leitner, PP, Luzzio, MJ et al. (1995). In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55: 603-609.
24. Tanizawa, A, Fujimori, A, Fujimori, Y and Pommier, Y (1994). Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842.
25. Holm, C, Covey, JM, Kerrigan, D and Pommier, Y (1989). Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368.
26. Jaxel, C, Kohn, KW, Wani, MC, Wall, ME and Pommier, Y (1989). Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469.
27. Solary, E, Bertrand, R and Pommier, Y (1994). Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma 15: 21-32.
28. Pourquier, P, Pilon, AA, Kohlhagen, G, Mazumder, A, Sharma, A and Pommier, Y (1997). Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 272: 26441-26447.
29. Pommier, Y, Pourquier, P, Fan, Y and Strumberg, D (1998). Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 83-105.
30. Gerrits, CJ, de Jonge, MJ, Schellens, JH, Stoter, G and Verweij, J (1997). Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952-962.
31. Collins, I, Weber, A and Levens, D (2001). Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 21: 8437-8451.
32. Shykind, BM, Kim, J, Stewart, L, Champoux, J and Sharp, PA (1997). Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev 11: 397-407.
33. Merino, A, Madden, KR, Lane, WS, Champoux, JJ and Reinberg, D (1993). DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365: 227-232.
34. Daoud, SS, Munson, PJ, Reinhold, W, Young, L, Prabhu, VV, Yu, Q et al. (2003). Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: A pharmacogenomic study. Cancer Res 63: 2782-2793.
35. Mayer-Kuckuk, P, Banerjee, D, Kemeny, N, Fong, Y and Bertino, JR (2002). Molecular therapies for colorectal cancer metastatic to the liver. Mol Ther 5: 492-500.
36. Chen, SH, Kosai, K, Xu, B, Pham-Nguyen, K, Contant, C, Finegold, MJ et al. (1996). Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res 56: 3758-3762.
37. Chen, SH, Chen, XH, Wang, Y, Kosai, K, Finegold, MJ, Rich, SS et al. (1995). Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92: 2577-2581.
38. Chen, CT, Lin, J, Li, Q, Phipps, SS, Jakubczak, JL, Stewart, DA et al. (2000). Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 11: 1983-1996.
39. Aldeguer, X, Debonera, F, Shaked, A, Krasinkas, AM, Gelman, AE, Que, X et al. (2002). Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology 35: 40-48.
40. Duguez, S, Feasson, L, Denis, C and Freyssenet, D (2002). Mitochondrial biogenesis during skeletal muscle regeneration. Am J Physiol Endocrinol Metab 282: E802-E809.
41. Honigman, A, Zeira, E, Ohana, P, Abramovitz, R, Tavor, E, Bar, I et al. (2001). Imaging transgene expression in live animals. Mol Ther 4: 239-249.